US FDA to seek panel's advice on 'complicated' matters with Novartis gouty arthritis drug
20 June 2011
Donna Young
Please Login to read the full article.
20 June 2011
Donna Young
Please Login to read the full article.
RELATED CONTENT
NEWS
- US FDA rejects Novartis gouty arthritis drug; seeks more safety data
- New malignancy concerns raised for Pfizer's JAK inhibitor ahead of AdCom
- US FDA: Risk of malignancies ‘small’ with Arcalyst in gout, but ‘may be real’
- Adherence, REMS expected AdCom focus for Gilead's Truvada in HIV PrEP
COMMENT
Other Informa Comment
EVENTS
Today
The Rembrandt Hotel, London
07 June 2012
The Rembrandt Hotel, London
12 June 2012
Annecy, France
JOB OF THE WEEK
Section Head (m/f)
DRA International/CIS Section
Section Head (m/f)
DRA International/CIS Section
